omiloxetine omiloxetine omiloxetine (omiloextinum, omiloxetino inn) was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the spanish pharmaceutical company, ferrer internacional, until 2005, when it was abandoned. omiloxetineclinical dataatc codenoneidentifiers iupac name 2--4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone cas number176894-09-0pubchem cid3047803chemspider2310120uniih8yi0ssf7bchemblchembl2105290comptox dashboard (epa)dtxsid30170205 chemical and physical dataformulac27h25f2no4molar mass465.497 g·mol−13d model (jsmol)interactive imagedensity1.3±0.1 g/cm3melting point228.65 °c (443.57 °f)boiling point587.2 °c (1,089.0 °f)solubility in water0.0015 mg/ml (20 °c) smiles fc1ccc(cc1)c(=o)cn3cc(c2ccc(f)cc2)(c3)coc4ccc5ococ5c4 inchi inchi=1s/c27h25f2no4/c28-21-5-1-18(2-6-21)24-11-12-30(15-25(31)19-3-7-22(29)8-4-19)14-20(24)16-32-23-9-10-26-27(13-23)34-17-33-26/h1-10,13,20,24h,11-12,14-17h2/t20-,24-/m1/s1key:fahgzanunvvdfl-hybuggrvsa-n rafael foguet also patented abaperidone.